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Inflammatory biomarker score and cancer:
A population-based prospective cohort
study
Leavitt Morrison1, Jari A. Laukkanen2,3, Kimmo Ronkainen2, Sudhir Kurl2, Jussi Kauhanen2 and Adetunji T. Toriola1*
Abstract
Background: Inflammation is associated with cancer but there are conflicting reports on associations of biomarkers
of inflammation with cancer risk and mortality. We investigated the associations of C-reactive protein (CRP) and
leukocyte count with cancer risk and mortality using individual biomarkers, and an inflammatory score derived from
both biomarkers.
Methods: We conducted this analysis among 2,570 men enrolled in the population-based, prospective Kuopio
Ischemic Heart Disease Risk Factor Study in Finland. During an average follow-up period of 26 years, 653 cancer
cases and 287 cancer deaths occurred. We computed a z-score for each participant, with the combined z-score
being the sum of each individual’s CRP and leukocyte z-scores. Multivariable-adjusted Cox proportional hazard
model was used to evaluate associations with cancer risk and mortality.
Results: Using individual biomarkers, elevated leukocyte count was associated with an increased risk of cancer
(RR = 1.31, 95 % CI 1.04-1.66), and cancer mortality (RR=, 95 % CI 1.39, 0.98-1.97). The corresponding results for CRP
were (RR = 1.23, 95 % CI 0.97-1.55) for risk and (RR = 1.15, 95 % CI 0.81-1.64) for cancer mortality. Associations of the
biomarkers with cancer appeared to be more robust using the combined z-score. HRs comparing men within the
highest z-score quartile to those within the lowest z-score quartiles were 1.47 (95 % CI 1.16-1.88, p-trend < 0.01) for
cancer risk, and 1.48 (95 % CI 1.03-2.14, p-trend = 0.09) for cancer mortality.
Conclusion: Our study suggests that inflammation is associated with cancer risk and mortality, and combining
inflammatory biomarkers into a score is a robust method of elucidating this association.
Keywords: Biomarkers, c-reactive protein, Inflammation, Leukocyte count, Cancer mortality
Background
Inflammation is associated with cancer risk and mortality
[1, 2]. Several cancer types arise from local inflammatory
states. For instance, inflammatory bowel disease [3], reflux
esophagitis [4], and chronic pancreatitis [5] are associated
with increased risk of colorectal, esophageal and pancre-
atic cancers, respectively. Nevertheless, there are conflict-
ing reports on the associations of biomarkers of systemic
inflammation with overall cancer risk and mortality. C-
reactive protein and leukocyte counts are biomarkers of
systemic inflammation that have been related to all-cause
cancer and cancer mortality in previous studies [6–12].
While some studies have demonstrated positive associa-
tions between biomarkers of inflammation and overall
cancer risk [6, 7] and mortality [8, 10, 12, 13], other
studies have not reported any association [9, 14, 15].
These results demonstrate a need to further evaluate
how biomarkers of systemic inflammation relate to
cancer risk and mortality.
Because the biomarkers are systemic, associations
between individual biomarkers and cancer may not be
always apparent. One inflammatory marker may correctly
classify some cases and misclassify others and this could
contribute to the differences in results reported in previ-
ous studies. Hence, combining inflammatory biomarkers
using an inflammatory score may provide a more accurate
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classification of inflammatory status [16]. Thus, an inflam-
matory score may be more robust compared to individual
biomarkers in the assessment of cancer risk. To elucidate
on the associations of inflammatory biomarkers with
cancer, we investigated the associations of CRP and
leukocyte count with cancer risk and mortality independ-
ently, as well as using a derived biomarker z-score
combining both biomarkers. We hypothesize that
combining CRP and leukocyte count would be a robust
method of elucidating the associations of biomarkers with
cancer risk and mortality.
Methods
Study population
This analysis was conducted among participants enrolled
in a prospective cohort study from Eastern Finland; the
Kuopio Ischemic Heart Disease Risk Factor Study
(KIHD). Detailed description of this cohort has been
provided in previous studies [17–19]. The KIHD was
originally designed to investigate risk factors for cardio-
vascular diseases, and other health related outcomes in a
population-based sample of middle-aged men from
Eastern Finland. Baseline examinations were conducted
between March 1984 and December 1989. The study
group is a representative sample of men living in Kuopio
and its surrounding rural communities who were aged 42,
48, 54 and 60 years at the time of baseline examination.
Of the 3235 eligible men, 2682 (83 %) volunteered to par-
ticipate and 198 men were excluded because of serious
disease. For the present study, we further excluded men
who had a history of cancer at baseline and those who had
incomplete data. Hence, 2,570 men were available for the
present analysis. Blood samples were collected from each
participant once at baseline examination. Baseline blood
samples were analysed for the C-reactive protein and
leucocyte count.
Cancer cases and cancer mortality
Incident cancer cases were derived from the Finnish
Cancer Registry (FCR). The FCR is population-based,
covers the whole of Finland and coverage is virtually
complete with no loss to follow-up. For solid tumours;
the registration is >99 % complete [20]. The FCR file
containing personal identity codes is annually matched
through computerized linkage with the cause of death
register at the Statistics Finland so that dates and cause
of deaths in cancer patients can be added to the FCR re-
cords [21]. The FCR file is also regularly linked with the
Central Population Register to ensure that the personal
identity codes are correct. Our study cohort was record
linked with the FCR data using the 11-digit personal
identity code mandatory to every resident of Finland
since 1961. Outcomes were assessed annually with the
help (linking) of the personal identity codes. All cancer
diagnoses (N = 653) that occurred between the study
entry (March 1984 to December 1989) and December
2012 were included. The most prevalent cancers were;
prostate (N = 231), lung (N = 87) and colorectal (N = 83)
cancers. Likewise, FCR file that contains personal iden-
tity codes is annually matched to the death register at
the Statistics Finland using computerized linkages. This
ensures that dates and causes of deaths are added to the
FCR records [21]. It is also regularly linked with the
Central Population Register to ensure that the personal
identity codes are correct. Due to the complete follow
up system of the Finnish population, there are no losses
to follow-up [21]. During the follow-up period 287 can-
cer deaths were reported, mainly from prostate, lung,
and colorectal cancers.
Assessment of covariates
The number of cigarettes, cigars, and pipefuls of tobacco
currently smoked daily, and duration of regular smoking
in years were recorded with a self-administered ques-
tionnaire, which was checked by an interviewer [19, 22].
A subject was defined as a smoker if he had ever
smoked on a regular basis and had smoked cigarettes, ci-
gars, or pipe within the past 30 days. Life-long exposure
to smoking (cigarette pack years) was estimated as the
product of the number of smoking years and the num-
ber of tobacco products smoked daily until the time of
baseline examination. Food consumption was assessed at
the time of blood sampling during the baseline phase of
the study. Subjects were instructed on the use of house-
hold measures for quantitative recording of their food
intake during the 4 days of data collection [23]. A nutri-
tionist gave the instructions and checked the completed
food intake records. Dietary intake of foods and nutri-
ents was calculated using NUTRICA software (version
2.5; National Public Health Institute, Turku). The soft-
ware is compiled using mainly Finnish values of nutrient
composition of foods, and takes into account losses of
vitamins in food preparation. The nutrient composition
of foods in the NUTRICA software used reflects data on
vitamin contents of fruits and vegetables [23]. Body
weight was measured using a balance scale and BMI was
computed as the ratio of weight to the square of height
(kg/m2). Cardiorespiratory fitness (maximal oxygen up-
take, VO2max) was defined as the highest value or the
plateau of directly measured oxygen consumption using a
respiratory gas analyzer (Mijnhardt, the Netherlands and
Medical Graphics, St. Paul, Minn.) [18]. One metabolic
equivalent corresponds to oxygen uptake of 3.5 mL/kg/
min. Alcohol consumption was assessed with a structured
quantity-frequency method using the Nordic Alcohol
Consumption Inventory [24]. The questionnaire assessed
alcohol consumption over the preceding 12 months. Usual
frequency of intake and usual dose per sitting (in glasses
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or bottles) were queried separately for each beverage (beer,
wine, spirits) with a structured response form.
Laboratory analysis
Laboratory assay for leukocyte count was undertaken at
the Institute of Public Health, University of Kuopio. Blood
leukocyte count was measured using a cell counter
(Coulter Counter Electronics Model DN, Luton, UK). The
between batch CV was below 4 %. CRP was quantified at
the laboratory of Clinical Chemistry, Kuopio University
Hospital. Serum C reactive protein concentration was
measured with an immunometric assay (Immulite High
Sensitivity C-reactive protein assay, DPC, Los Angeles,
USA). The between batch coefficient of variation (CV)
was 3.1 % at the CRP level of 3.2 mg/l. The between batch
CV was below 5 %.
Statistical analysis
We compared baseline characteristics by cancer status
using Chi-square (Χ2) test for categorical variables and
Wilcoxon rank sum for continuous variables. Continu-
ous variables are reported as mean (standard deviation)
while categorical variables are reported as frequencies
(percentages).
Cox proportional hazard model was used to evaluate
associations of the biomarkers with cancer risk and mor-
tality. We categorized the biomarkers into quartiles based
on the distribution in the study population. Relative Risks
(RRs) and 95 % confidence intervals (95 % CI) were calcu-
lated for each biomarker. We evaluated the associations of
the biomarkers with cancer risk and mortality in 3 models,
adjusting for confounders. Confounders were selected if
the p-value associated with the variable was <0.10 in the
models. In model 1, we adjusted for only age at baseline
examination. In model 2, we additionally adjusted for
examination year, alcohol intake (grams/week), energy in-
take (KJ/4-day period) and cardiorespiratory fitness. In
model 3, we adjusted for all the variables in model 2 as
well as smoking (pack-years). Body mass index (BMI) was
not included in the multivariable analysis, as the p-value
for BMI in the model was >0.10 and including BMI did
not have any impact on the effect estimates.
In addition to individual biomarker analysis, the bio-
markers were analyzed together using a standardized z-
score. To compute the z-score, each biomarker was
normalized using a z-transformation. Z-score was com-
puted for each participant based on the subject’s biomarker
levels (x), study mean (μ) and study standard deviation (σ).
We computed the z-scores thus; z-score = (x - μ)/σ. The
combined z-score was the sum of the subject’s individual
CRP and leukocyte z-scores. We categorized study partici-
pants into quartiles of the combined z-score and evaluated
associations with cancer risk and mortality using a Cox
proportional hazards model, adjusted for confounders.
All tests were two-sided with significance considered
to be a p-value < 0.05. Tests for trend were assessed
using the Wald test. Analyses were performed using SAS
version 9.3 (SAS Institute, Cary, NC).
Results
Table 1 describes baseline characteristics by incident
cancer status. Six hundred and fifty three men developed
cancer and 287 men died from cancer during an average
follow-up period of 26 years (23–28). Men who developed
cancer were more likely to be older (53.9 vs. 52.7 years,
p-value < 0.01), smokers (37.7 % vs. 28.0 %, p-value < 0.01),
consume more alcohol (81.2 vs. 73.7 g/week, p-value =
0.03), and have higher leukocyte counts (5.84 vs. 5.66
109/L, p-value < 0.01). There was a modest correlation
(r = 0.31, p-value < 0.01) between CRP and leukocyte
count (data not shown).
There were positive associations between CRP, leukocyte
count, and cancer risk, which were attenuated after
adjustment for smoking (Table 2). In age-adjusted
analysis (model 1), men within the highest quartiles
of CRP (RR = 1.49, 95 % CI 1.20-1.86, p-trend = 0.01)
and leukocyte count (RR = 1.64, 95 % CI 1.32-2.03, p-
trend = 0.01) had higher risks of cancer compared to
those within the lowest quartiles. Similar results were
observed in multivariable-adjusted analysis not adjusted
for smoking (model 2). The HRs were 1.37 (95 % CI 1.09-
1.72, p-trend = 0.05) for CRP, and 1.56 (95 % CI 1.25-1.94,
p-trend = 0.02) for leukocyte count. However, the associa-
tions between CRP and leukocyte count and cancer risk
were attenuated after further adjustment for smoking
(model 3). RRs comparing men within the highest quar-
tiles of CRP and leukocyte count to those within the low-
est quartiles were 1.23 (95 % CI 0.97-1.55, p-trend = 0.18)
and 1.31 (95 % CI 1.04-1.66, p-trend = 0.19), respectively.
We observed similar associations with cancer mortal-
ity (Table 3). In the age-adjusted model, the HRs of can-
cer mortality comparing men within the fourth quartile
of CRP and leukocyte count to those within the first
quartile were 1.65 (95 % CI 1.18-2.31, p-trend = 0.02)
and 2.09 (95 % CI 1.52-2.89, p-trend = 0.01), respectively.
The HRs were 1.40 (95 % CI 0.99-1.99, p-trend = 0.43)
for CRP and 1.88 (95 % CI 1.36-2.62, p-trend = 0.04) for
leukocyte count in multivariable analyses not adjusted
for smoking. As with cancer risk, the further adjustments
for smoking attenuated the observed associations between
biomarkers and cancer mortality; RR = 1.15 (95 % CI 0.81-
1.64, p-trend = 0.43) for CRP, and RR = 1.39 (95 % CI 0.98-
1.97, p-trend = 0.42) for leukocyte count.
In multivariable analysis conducted using z-score, we
observed consistent positive associations with cancer
risk and mortality in all models, regardless of adjustment
for smoking. In multivariable model adjusted for all con-
founding factors, men within the highest z-score quartile
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Table 2 Hazard Ratios (HR) and 95 % Confidence Intervals (CI) of cancer risk by quartiles of biomarkers and z-score
Q1 Q2 Q3 Q4 P-trend
Leukocyte Count
No of Cases/Total 157/672 146/638 170/630 180/630
Age-adjusted 1.0 (ref) 1.02 (0.82-1.28) 1.29 (1.03-1.60) 1.64 (1.32-2.03) 0.01
Multivariable1 1.0 (ref) 1.01 (0.80-1.26) 1.24 (0.99-1.54) 1.56 (1.25-1.94) 0.02
Multivariable2 1.0 (ref) 0.97 (0.77-1.22) 1.15 (0.92-1.43) 1.31 (1.04-1.66) 0.19
C-reactive protein
No of Cases/Total 151/639 168/643 163/645 171/643
Age-adjusted 1.0 (ref) 1.13 (0.90-1.40) 1.22 (0.97-1.52) 1.49 (1.20-1.86) 0.01
Multivariable1 1.0 (ref) 1.09 (0.88-1.37) 1.17 (0.93-1.46) 1.37 (1.09-1.72) 0.05
Multivariable2 1.0 (ref) 1.08 (0.87-1.35) 1.11 (0.88-1.39) 1.23 (0.97-1.55) 0.18
Z-score3
No of Cases/Total 139/642 163/643 168/643 183/642
Multivariable2 1.0 (ref) 1.18 (0.94-1.49) 1.26 (1.00-1.59) 1.47 (1.16-1.88) <0.01
1Multivariable model adjusted for age, examination year, alcohol intake, cardiorespiratory fitness and energy intake
2Multivariable model adjusted for age, examination year, alcohol intake, cardiorespiratory fitness, energy intake and smoking
3Z-score was computed for each participant based on the subject’s biomarker levels (x), study mean (μ) and study standard deviation (σ)
We computed the individual z-scores thus; z-score = (x - μ)/σ. The combined z-score is the sum of the subject’s individual CRP and leukocyte z-scores







Age, years 52.71(5.27) 53.91(4.53) <0.01
Body mass index (kg/m2)
<25 599 (31.25 %) 202 (30.93 %)
25-29.99 984 (51.33 %) 345 (52.83 %)
30-34.99 277 (14.45 %) 87 (13.32 %)
≥35 57 (2.97 %) 19 (2.91 %)
Smoking history <0.01
Non-smoker 1380 (71.99 %) 407 (62.33 %)
Smoker 537 (28.01 %) 246 (37.67 %)
Pack-years <0.01
<10 Pack-years 96 (5.01 %) 48 (7.35 %)
10-20 Pack-years 121 (6.31 %) 43 (6.58 %)
>20 Pack-years 320 (16.69 %) 155 (23.74 %)
Alcohol consumption, g/week 73.68 (134.18) 81.20 (145.21) 0.03
Energy intake, KJ, (4 day mean) 9912.31 (2599.35) 9674.02 (2536.23) 0.03
Vegetable intake, g (4 day mean) 286.21 (126.58) 287.53 (122.45) 0.75
Fruit and berry intake, g (4 day mean) 161.30 (146.76) 157.69 (138.80) 0.81
Cardiorespiratory fitness (VO2 max) 30.61 (7.63) 30.06 (7.52) 0.05
Family history of any cancer 0.21
No 1465 (76.42 %) 483 (73.97 %)
Yes 452 (23.58 %) 170 (26.03 %)
Leukocyte count, 1,000/μl 5.66 (1.56) 5.84 (1.67) <0.01
C-reactive protein, mg/l 2.43 (4.22) 2.44 (3.83) 0.23
Continuous values are presented as mean (standard deviation) and categorical values as number (%)
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had a higher risk of cancer when compared to those
within the lowest z-score quartile; RR = 1.47 (95 % CI
1.16-1.88, p-trend < 0.01). Similarly, men within the
highest z-score quartile had increased cancer mortality;
RR of 1.48 (95 % CI 1.03-2.14), although the trend test
was not statistically significant (p-trend = 0.09). We ob-
served no evidence of interaction by smoking status for
cancer risk and mortality for analyses using the individ-
ual biomarkers and the z-score. For instance, the multi-
variable adjusted HR for cancer incidence among men
within the fourth quartile of z-score compared to those
within the first quartile was 1.32 (95 % CI 0.96-1.80) for
non-smokers and 1.46 (95 % CI 0.93-2.29) for smokers
(data not shown). In addition, there was no interaction
between CRP and leucocyte count.
Discussion
In this population-based prospective cohort study with
long follow-up, a combined inflammatory score was as-
sociated with increased risk of incident cancer. Data
from this study further support the growing evidence
that inflammation plays a role in cancer risk and mortal-
ity. Furthermore, our results indicate that combining
biomarkers of inflammation is robust method of eluci-
dating the associations of inflammation with cancer risk
and mortality.
Similar to our findings using individual biomarkers, a
recent analysis within the European Prospective Investiga-
tion of Cancer (EPIC)-Norfolk cohort demonstrated an
association between CRP and cancer mortality although it
was not significant when other confounders were taken in
account [9]. In sex-stratified analysis [9], men within the
highest CRP levels had a non-statistically significant 1.17-
fold increased risk of cancer death compared to men with
low levels of CRP, similar to what we observed in our
study (RR = 1.23). In another study among males in 3 large
cohorts from the United Kingdom, CRP and leukocyte
counts were associated with increased risk of smoking-
related cancers but the associations were confounded by
smoking such that adjustment for smoking completely at-
tenuated the associations [15]. Smoking is associated with
changes in CRP concentrations and is thus an important
confounder when relating CRP to cancer risk or mortality
[25]. Likewise, a study among Koreans did not report any
associations between leukocyte count and cancer death
among men and women, although elevated leukocyte
count was associated all-cause mortality [14]. Hence, our
observations of positive associations in analyses using z-
scores underscore the utility of combining inflammatory
biomarkers into a score when evaluating the associations
of inflammatory biomarkers with cancer.
Other studies within the Swedish Apolipoprotein
MOrtality RISk (AMORIS) and The National Health and
Nutrition Examination Survey (NHANES) III have also
evaluated the utility of biomarker scores in relation to
overall cancer risk and mortality [26–28]. However, our
methods of deriving the biomarker scores differed com-
pared with the AMORIS and NHANES III study. In one
of the studies conducted within the AMORIS cohort,
the authors derived an inflammation-based predictive
score (IPS) using CRP and leukocyte count, where they
classified the cohort into 2 groups and assigned a score
of 1 if an individual had both CRP and leukocyte count
above a clinical cut-off point and a score of 0 otherwise
[26]. Having an IPS score of 1 was associated with in-
creased overall cancer risk compared with a score of 0.
Table 3 Hazard Ratios (HR) and 95 % Confidence Intervals (CI) of cancer mortality by quartiles of biomarkers and z-score
Q1 Q2 Q3 Q4 P-trend
Leukocyte Count
No of Cases/Total 62/672 54/638 79/630 92/630
Age-adjusted 1.0 (ref) 0.95 (0.66-1.37) 1.48 (1.06-2.07) 2.09 (1.52-2.89) 0.01
Multivariablea 1.0 (ref) 0.93 (0.65-1.34) 1.38 (0.99-1.93) 1.88 (1.36-2.62) 0.04
Multivariableb 1.0 (ref) 0.87 (0.60-1.25) 1.20 (0.85-1.68) 1.39 (0.98-1.97) 0.42
C-reactive protein
No of Cases/Total 61/639 73/643 75/645 78/643
Age-adjusted 1.0 (ref) 1.18 (0.84-1.66) 1.37 (0.97-1.92) 1.65 (1.18-2.31) 0.02
Multivariablea 1.0 (ref) 1.13 (0.80-1.59) 1.25 (0.88-1.75) 1.40 (0.99-1.99) 0.12
Multivariableb 1.0 (ref) 1.10 (0.78-1.55) 1.12 (0.79-1.59) 1.15 (0.81-1.64) 0.43
Z-score
No of Cases/Total 54/642 65/643 77/643 91/642
Multivariableb 1.0 (ref) 1.12 (0.78-1.61) 1.30 (0.91-1.86) 1.48 (1.03-2.14) 0.09
aMultivariable model adjusted for age, examination year, alcohol intake, cardiorespiratory fitness and energy intake
bMultivariable model adjusted for age, examination year, alcohol intake, cardiorespiratory fitness, energy intake and smoking
Morrison et al. BMC Cancer  (2016) 16:80 Page 5 of 7
The authors, however, did not adjust for smoking, which
is an important confounder and did not evaluate cancer
mortality associations. In the NHANES III study and an-
other study within the AMORIS cohort, a quantitative
score, ranging from 0-4, derived by adding a number of
biomarkers (CRP, albumin, gamma-glutamyl transferase,
and HDL cholesterol) with abnormal values was posi-
tively associated with cancer mortality [27, 28]. These
biomarkers, however, have different mechanistic import-
ance, with CRP considered the sole biomarker of sys-
temic inflammation of the 4 biomarkers used. Although
there are key differences compared with our current
study in how the scores were derived, these offer robust
evidence for the utility of a biomarker score when evalu-
ating cancer risk and mortality.
On the other hand, some studies have reported positive
associations of CRP and leukocyte count with cancer risk
and mortality using the individual markers alone and the
reasons may be due to differences in age and gender com-
positions the study populations [10, 12]. Our study is lim-
ited to men while these studies had men and women in
their cohorts. In addition, participants in the Health Aging
and Body Composition cohort are much older compared
with those in our study cohort with a minimum age at re-
cruitment of 70 years, compared with 48 years in our study.
Our study has the following limitations. We related
CRP concentration and leukocyte count at one-time
point to cancer risk and mortality. This might underesti-
mate any associations, especially between CRP and cancer.
Published data indicate that relating a single measurement
of CRP to cancer risk underestimates the true strength of
the association [29]. Our study cohort consisted of only
Caucasian White men; hence our results may not be
generalizable to women and other racial groups. We
evaluated the associations of the biomarkers with over-
all cancer risk and mortality and some of the cancer
sites included may not have an inflammatory origin.
This may attenuate any possible associations. Neverthe-
less, three cancers; prostate (N = 231), lung (N = 87)
and colorectal (N = 83) constitute 61 % of the incident
cancer cases in our cohort. Inflammation has been
shown to contribute to these three cancers and it is pos-
sible that these 3 cancers drive the overall associations we
observed in our study.
In spite of the limitations, our study has many strengths.
It is population-based, prospective in nature, with a long
follow-up period and virtually no loss-to follow up. Add-
itionally, the Finnish Cancer Registry is >99 % complete
and is annually linked to the national cause of death regis-
try. Because of this, we were able to include all deaths that
occurred in the cohort in our analysis. Furthermore, many
confounders were measured in the KIHD study, which
allowed us to comprehensively explore their roles in the
observed associations.
Conclusions
In summary, our data support evidence linking inflamma-
tion with cancer and suggest that combining inflammatory
biomarkers into a score is a robust method of elucidating
the associations of inflammatory biomarkers with cancer
risk and mortality. These results require confirmation. In
addition, the utility of including additional inflammatory
biomarkers to derive a clinically useful risk score could be
explored in future prospective studies.
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